Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna ... 2025. The gross proceeds from the initial public offering ...

Conference Call and Webcast BiomX intends to host a conference call and a live audio webcast at a later date to discuss its fourth quarter and full year 2024 financial results, in conjunction with its ...

Food allergy prevalence was lower in those with cystic fibrosis vs. the general pediatric population. The prevalence of food allergy significantly differed by sex and pancreatic enzyme replacement ...

Successfully raised approximately $12 million in gross proceeds through financings ... Initiated exploration of real-world evidence in cystic fibrosis patients, preparing for regulatory ...